Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.130.03%
QQQ
709.610.06%
BTC/USD
77857.980.4276%
DIA
524.660.03%
GLD
393.070.06%
TLT
80.93-

TriSalus Life Sciences Inc

TLSINASDAQ
Trade with Public
Trade with Public
$4.77
0.102.25%
At close: Sep 14, 5:00 PM EST
$4.77
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

TriSalus Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for TriSalus Life Sciences (TLSI).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$11Upside to Avg. PT+122.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026HC Wainwright & Co.Swayampakula RamakanthInitiateBuy$11
May 13, 2026Lake StreetFrank TakkinenPT CutBuy$10→$8
More with Benzinga EdgeGet Access

Analyst Ratings News

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiate coverage: Buy ratings for Robinhood ($170), TriSalus ($11), Kodiak AI ($8); Underperform for Deckers ($70).
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8

Lake Street analyst Frank Takkinen maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $10 to $8.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $7

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $12 to $7.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $11 Price Target

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved